Heart Disease Drug Trials Face Setbacks Amidst Longevity Industry Boom
Translated & summarized from Globes by baba
Major pharmaceutical companies like Novartis and Novo Nordisk have faced setbacks in clinical trials for new heart disease drugs targeting factors like LP(a) cholesterol and inflammation. These failures, despite reducing biological markers, did not lower heart attack rates, raising questions about scientific understanding and increasing the difficulty and cost of developing new cardiovascular treatments. However, ongoing research in areas like gene therapy, improved medical devices, and better patient adherence offers continued hope for advancing heart health.
The story in 5 lines · by baba
- Novartis lost $34 billion after heart drug trials failed to reduce heart attacks.
- New cardiovascular drugs must now prove reduced mortality, not just markers.
- LP(a) cholesterol is a significant risk factor affecting one in five people.
- Despite setbacks, research in gene therapy and medical devices continues.
- Low patient adherence to existing treatments remains a major challenge.
The burgeoning longevity industry, attracting significant investment, is facing scrutiny as major pharmaceutical companies experience setbacks in developing new heart disease treatments. Novartis recently lost $34 billion in market value following the failure of two clinical trials. One trial aimed to target LP(a), a substance similar to "bad" LDL cholesterol that significantly increases heart attack risk and affects one in five people, often due to genetics rather than lifestyle. Despite lowering LP(a) levels, the drug did not reduce heart attacks or deaths, raising questions about the underlying scientific mechanisms. This failure impacted other companies developing LP(a) drugs, such as AstraZeneca and Eli Lilly, and followed a similar disappointment with a Novo Nordisk drug that reduced arterial inflammation but not heart attacks.
These setbacks highlight the increasing difficulty in developing new heart medications. While average life expectancy has risen due to advancements in cardiovascular care, with an estimated three to four years added in the last 50 years, the US still sees 600,000 first-time heart attacks annually. Experts note that while treatments have improved quality of life, new drugs must now demonstrate a reduction in actual mortality or morbidity, not just biological markers, compared to existing therapies. These trials are lengthy and costly, often taking five years and hundreds of millions of dollars.
Despite these challenges, some progress continues. Professor Michael Shechter of Sheba Medical Center points to the Novo Nordisk drug Wegovy showing cardiac benefits beyond weight loss, and SGLT2 inhibitors, used for diabetes, proving effective in heart failure. He remains optimistic about LP(a) therapies, noting Eli Lilly's approach targets a 95% reduction, potentially making a difference where Novartis's 70% did not. Novartis is continuing to test its drug in patients with heart valve stenosis. Other promising areas include gene therapy for cholesterol reduction and improved medical devices, such as stents and devices to support heart walls in cases of heart failure. A significant issue remains low patient adherence to existing treatments, with about 50% not taking preventative medications as prescribed.